Name: |
Ulrich, Karen |
 |
Date of Birth: |
05. Oktober 1994 |
|
Address: |
Universität Bayreuth; LS Biopolymere Universitätsstraße 30, 95447 Bayreuth Axolabs GmbH Fritz-Hornschuch-Straße 8, 95326 Kulmbach |
|
E-Mail: |
Current Position |
|
| since 03/2018 | external master thesis, Axolabs GmbH, Kulmbach |
Education |
|
| 04/2016 | Bachelor of Science: Biochemistry, U Bayreuth |
| since 04/2016 | Master programme Biochemistry and molecular Biology, U Bayreuth |
Additional Information |
|
| 04/2017 - 08/2017 | ERASMUS research programme on the subject of "Ex-vivo application of an artificial membrane fusion system" at Universiteit Leiden, Netherlands; Group of Prof. Dr. Alexander Kros (Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry) under supervision of Prof. Dr. Klaus Ersfeld (Dept. of Genetics, U Bayreuth) |
| 10/2017 - 03/2018 | Research programme on the subject of "synthesis, stability and biological activity of synthetic RIG-I agonists" in cooperation with Dr. Philipp Hadwiger (Axolabs GmbH, Kulmbach) under supervision of Prof. Dr. Birgitta Wöhrl (Dept. of Biopolymers, U Bayreuth) |
Research Interests |
Retinoic acid-inducible gene I (RIG-I) is a cytosolic immune receptor which recognizes released pathogen-specific nucleic acids of an virus infection within the cell. After recognition and activation of RIG-I, a signalling cascade is initiated, which induces apoptosis of the infected cell. If a synthetic pathogen-derived RNA-duplex is injected into a cancer cell, the double stranded RNA will be recognized by RIG-I and the cancer cell will be devitalised through immune cells. In the course of my master thesis such synthetic RIG-I agonists will be designed, synthesised and the immunological activity will be analysed. Thus, an highly effective and stable RIG-I agonist should be synthesised and analysed referring to published structures and sequence lenghts to become a potential immune therapeutic. |